Tertatolol is a noncardioselective beta-blocker without intrinsic
sympathomimetic activity. In a preliminary 3-month open study, it was shown that T was devoid of any atherogenic effect since
HDL-cholesterol (HDL-C) and
apoprotein levels did not change for 3 months of
therapy. To investigate the long-term effects of
tertatolol on the
lipid profile and its safety in hypertensive patients with
peripheral arterial disease (PAD), a 9-month, randomized, double-blind, parallel group study was carried out in 40 patients.
Tertatolol 5 mg once daily was compared with
metoprolol 200 mg once daily. If BP was not controlled after 2 months, a vasodilatator agent,
dihydralazine, was added at the lowest dose required to control BP (diastolic BP < 90 mm Hg).
Lipoprotein fractions and
apoproteins were assayed before (M0) and after 2, 6 and 9 months of
therapy. At the same occasions,
peripheral arterial disease (PAD) was evaluated on exercise tests carried out on a treadmill and on the regional blood flow measured in the ankle arteries by the Doppler technique. Four patients were not eligible for analysis. In the
tertatolol group, 1 patient with a normal BP, and 2 patients who dropped out, 1 because of persistent
nausea and 1 because of personal reasons. In the
metoprolol group, 1 patient refused to take
dihydralazine. In the 35 fully documented patients, BP control was achieved in both groups. The mean reductions in supine systolic/diastolic BP were 31.4/14.6 and 34.7/17.1 mm Hg in the
tertatolol and
metoprolol groups, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)